Clinical Trial Update: Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients

View source ↗

Summary

An ongoing clinical trial sponsored by Migal Galilee Research Institute tests selective targeting of pathogenic CD8 T cells in Type 1 diabetes patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Snippet

Sponsor: Migal Galilee Research Institute | Conditions: Type I Diabetes | Status: UNKNOWN